Cyclo Therapeutics Inc - Ordinary Shares - Class A Stock
Cyclo Therapeutics Inc - Ordinary Shares - Class A Stock price
Key metrics
| Market capitalization | $17.20m |
| Enterprise Value | $28.48m |
| P/E (TTM) P/E ratio | negative |
| EV/Sales (TTM) EV/Sales | 32.74 |
| P/S ratio (TTM) P/S ratio | 19.77 |
| P/B ratio (TTM) P/B ratio | negative |
| Revenue growth (TTM) Revenue growth | -8.52% |
| Revenue (TTM) Revenue | $870.00k |
| EBIT (operating result TTM) EBIT | $-24.68m |
Is Cyclo Therapeutics Inc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
Cyclo Therapeutics Inc - Ordinary Shares - Class A Stock Analysis
Analyst Opinions
1 Analyst has issued a forecast Cyclo Therapeutics Inc - Ordinary Shares - Class A:
Analyst Opinions
1 Analyst has issued a forecast Cyclo Therapeutics Inc - Ordinary Shares - Class A:
Financial data from Cyclo Therapeutics Inc - Ordinary Shares - Class A
| Sep '24 |
+/-
%
|
||
| Revenue | 0.87 0.87 |
8%
8%
|
|
| Gross Profit | -2.64 -2.64 |
0%
0%
|
|
| EBITDA | -25 -25 |
27%
27%
|
EBIT (Operating Income) EBIT | -25 -25 |
27%
27%
|
| Net Profit | -25 -25 |
28%
28%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Cyclo Therapeutics Inc - Ordinary Shares - Class A directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cyclo Therapeutics Inc - Ordinary Shares - Class A Stock News
Company Profile
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The firm focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
| Head office | United States |
| CEO | Scott Fine |
| Employees | 8 |
| Founded | 1990 |
| Website | www.cyclotherapeutics.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
